Coronary artery bypass surgery perioperative management of myocardial dysfunction: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 3: Line 3:
{{CMG}}; {{AOEIC}} {{VK}}
{{CMG}}; {{AOEIC}} {{VK}}


==ACCF/AHA Guidelines for Perioperative Myocardial Dysfunction==
==2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)<ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 |volume=  | issue=  | pages=  | pmid=22064599 | doi=10.1161/CIR.0b013e31823c074e | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599  }} </ref>==
 
===Perioperative Myocardial Dysfunction (DO NOT EDIT)<ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume=  | issue=  | pages=  |pmid=22064599 |doi=10.1161/CIR.0b013e31823c074e | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599  }} </ref>===
{|class="wikitable"
{|class="wikitable"
|-
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In the absence of severe, symptomatic aorto-iliac occlusive disease or [[peripheral artery disease]], the insertion of an intra-aortic balloon is reasonable to reduce mortality rate in [[CABG]] patients who are considered to be at high risk (eg, those who are undergoing reoperation or have [[LVEF]] <30% or left main [[CAD]]).<ref name="pmid12400750">{{cite journal| author=Christenson JT, Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Ohman EM et al.| title=Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. | journal=Ann Thorac Surg | year= 2002 | volume= 74 | issue= 4 | pages= 1086-90; discussion 1090-1 | pmid=12400750 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12400750  }} </ref><ref name="pmid10509987">{{cite journal| author=Christenson JT, Simonet F, Badel P, Schmuziger M| title=Optimal timing of preoperative intraaortic balloon pump support in high-risk coronary patients. | journal=Ann Thorac Surg | year= 1999 | volume= 68 | issue= 3 | pages= 934-9 | pmid=10509987 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10509987  }} </ref><ref name="pmid12869172">{{cite journal| author=Christenson JT, Licker M, Kalangos A| title=The role of intra-aortic counterpulsation in high-risk OPCAB surgery: a prospective randomized study. | journal=J Card Surg | year= 2003 | volume= 18 | issue= 4 | pages= 286-94 | pmid=12869172 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12869172  }} </ref><ref name="pmid11420164">{{cite journal| author=Christenson JT, Schmuziger M, Simonet F| title=Effective surgical management of high-risk coronary patients using preoperative intra-aortic balloon counterpulsation therapy. | journal=Cardiovasc Surg | year= 2001 | volume= 9 | issue= 4 | pages= 383-90 | pmid=11420164 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11420164  }} </ref><ref name="pmid15246896">{{cite journal| author=Urban PM, Freedman RJ, Ohman EM, Stone GW, Christenson JT, Cohen M et al.| title=In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. | journal=Am J Cardiol | year= 2004 | volume= 94 | issue= 2 | pages= 181-5 | pmid=15246896 | doi=10.1016/j.amjcard.2004.03.058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15246896  }} </ref><ref name="pmid16342217">{{cite journal| author=Santa-Cruz RA, Cohen MG, Ohman EM| title=Aortic counterpulsation: a review of the hemodynamic effects and indications for use. | journal=Catheter Cardiovasc Interv | year= 2006 | volume= 67 | issue= 1 | pages= 68-77 | pmid=16342217 | doi=10.1002/ccd.20552 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16342217  }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''1.''' In the absence of severe, symptomatic aorto-iliac occlusive disease or PAD, the insertion of an intraaortic balloon is reasonable to reduce mortality rate in CABG patients who are considered to be at high risk (eg, those who are undergoing reoperation or have LVEF <30% or left main CAD).1021–1026 (Level of Evidence: B)<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.<ref name="pmid18721510">{{cite journal| author=Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N et al.| title=Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). | journal=Am J Cardiol | year= 2008 | volume= 102 | issue= 5 | pages= 546-51 | pmid=18721510 | doi=10.1016/j.amjcard.2008.04.069 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi? ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''2.''' Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.200 (Level of Evidence: B)<nowiki>"</nowiki>
|}
|}


Revision as of 16:53, 8 November 2012

Coronary Artery Bypass Surgery Microchapters

Home

Patient Information

Overview

Pathophysiology

Saphenous Vein Graft Disease
Other Non-Atherosclerotic Saphenous Vein Graft Diseases

Indications for CABG

Prognosis

Diagnosis

Imaging in the Patient Undergoing CABG

Chest X Ray

Angiography

CT Angiography
MRI Angiography

Trans-Esophageal Echocardiography

Treatment

Goals of Treatment

Perioperative Management

Perioperative Monitoring

Electrocardiographic Monitoring
Pulmonary Artery Catheterization
Central Nervous System Monitoring

Surgical Procedure

Anesthetic Considerations
Intervention in left main coronary artery disease
The Traditional Coronary Artery Bypass Grafting Procedure (Simplified)
Minimally Invasive CABG
Hybrid coronary revascularization
Conduits Used for Bypass
Videos on Spahenous Vein Graft Harvesting
Videos on Coronary Artery Bypass Surgery

Post-Operative Care and Complications

Pharmacotherapy in patients undergoing CABG CABG

Special Scenarios

Anomalous Coronary Arteries
COPD/Respiratory Insufficiency
Existing Renal Disease
Concomitant Valvular Disease
Previous Cardiac Surgery
Menopause
Carotid Disease evaluation before surgery

Coronary artery bypass surgery perioperative management of myocardial dysfunction On the Web

Most recent articles

Most cited articles

Review articles

CME programs

powerpoint slides

Images

Ongoing trials at clinical trials.gov

US National guidelines clearinghouse

NICE guidance

FDA on Coronary artery bypass surgery perioperative management of myocardial dysfunction

CDC on Coronary artery bypass surgery perioperative management of myocardial dysfunction

Coronary artery bypass surgery perioperative management of myocardial dysfunction in the news

Blogs on Coronary artery bypass surgery perioperative management of myocardial dysfunction|-

Directions to Hospitals Performing Coronary artery bypass surgery perioperative management of myocardial dysfunction

Risk calculators for Coronary artery bypass surgery perioperative management of myocardial dysfunction

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]

Perioperative Myocardial Dysfunction (DO NOT EDIT)[1]

Class IIa
"1. In the absence of severe, symptomatic aorto-iliac occlusive disease or peripheral artery disease, the insertion of an intra-aortic balloon is reasonable to reduce mortality rate in CABG patients who are considered to be at high risk (eg, those who are undergoing reoperation or have LVEF <30% or left main CAD).[2][3][4][5][6][7] (Level of Evidence: B)"
"2. Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.

References

  1. ↑ 1.0 1.1 Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.
  2. ↑ Christenson JT, Cohen M, Ferguson JJ, Freedman RJ, Miller MF, Ohman EM; et al. (2002). "Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery". Ann Thorac Surg. 74 (4): 1086–90, discussion 1090-1. PMID 12400750.
  3. ↑ Christenson JT, Simonet F, Badel P, Schmuziger M (1999). "Optimal timing of preoperative intraaortic balloon pump support in high-risk coronary patients". Ann Thorac Surg. 68 (3): 934–9. PMID 10509987.
  4. ↑ Christenson JT, Licker M, Kalangos A (2003). "The role of intra-aortic counterpulsation in high-risk OPCAB surgery: a prospective randomized study". J Card Surg. 18 (4): 286–94. PMID 12869172.
  5. ↑ Christenson JT, Schmuziger M, Simonet F (2001). "Effective surgical management of high-risk coronary patients using preoperative intra-aortic balloon counterpulsation therapy". Cardiovasc Surg. 9 (4): 383–90. PMID 11420164.
  6. ↑ Urban PM, Freedman RJ, Ohman EM, Stone GW, Christenson JT, Cohen M; et al. (2004). "In-hospital mortality associated with the use of intra-aortic balloon counterpulsation". Am J Cardiol. 94 (2): 181–5. doi:10.1016/j.amjcard.2004.03.058. PMID 15246896.
  7. ↑ Santa-Cruz RA, Cohen MG, Ohman EM (2006). "Aortic counterpulsation: a review of the hemodynamic effects and indications for use". Catheter Cardiovasc Interv. 67 (1): 68–77. doi:10.1002/ccd.20552. PMID 16342217.
Retrieved from "https://www.wikidoc.org/index.php?title=Coronary_artery_bypass_surgery_perioperative_management_of_myocardial_dysfunction&oldid=792380"